MODULATORY EFFECT OF PTEROSTILBENE ON CHANGES IN THE FATTY ACID COMPOSITION IN STREPTOZOTOCIN - NICOTINAMIDE INDUCED DIABETES.
Main Article Content
Keywords
Pterostilbene, Tetrahydrocurcumin, palmitic, stearic, oleic acid linolenic acid, arachidonic acid, Diabetes
Abstract
P.marsupium has been used in the treatment of toothache, diarrhoea, heartburn, urinary tract infections, boils, sores and skin diseases. Pterocarpus marsupium has been used for many years in the treatment of diabetes mellitus. Pterostilbene was found to be one of the active constituents in the extracts of the heartwood of Pterocarpus marsupium. Pterostilbene is a useful bioactive compound in preventing type 1 diabetes, insulin resistance and type 2 diabetes in animal models. Plants play a major role in the introduction of new therapeutic agents and have received much attention as sources of biologically active substances. The aim of this study was to evaluate the effect of Pterostilbene on blood glucose, plasma insulin and fatty acid composition of total lipids in liver, kidney and brain of control and streptozotocin (STZ)-nicotinamide diabetic rats. The analysis of fatty acids showed that there was a significant increase in the concentrations of palmitic acid (16:1), stearic acid (18:0) and oleic acid (18:1) acid in liver, kidney and brain, whereas the concentrations of linolenic acid (18:3) and arachidonic acid (20:4) were significantly decreased. Oral administration of the Pterostilbene (40 mg/kg body weight) for 45 days to diabetic rats decreased the concentrations of fatty acids, viz., palmitic, stearic, and oleic acid whereas linolenic and arachidonic acid were elevated.
References
1. World Health Organization (WHO). (2003). The expert committee on the diagnosis and classification of diabetes mellitus. Diab Care, 26:5-20.
2. Haffner, S.M., Lehto, S., Rönnemaa, T., Pyörälä, K., Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339: 229-234.
3. Eder, H.A., Bergman, M. (1990). Metabolism of plasma lipids and lipoproteins.
Diabetes Mellitus: Theory and Practice, 3rd ed. Medical Examination Publishing, New York. 61-72.
4. UKPDS. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352: 837-853.
5. Deedwania, P.C. (2000) Hypertension and diabetes: new therapeutic options. Arch Intern Med, 160:1585-1594.
6. Cameron, N.E., Cotter, M.A. (1999). Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pract, 45:137-146.
7. Faas, F.H., Dang, A.Q., Kemp, K., Norman, J., Carter, W.J. (1988). Red blood cell and plasma fatty acid composition in diabetes mellitus. Metabolism 37:711-713.
8. Seigneur, M., Freyburger, G., Gin, H., Claverie, M., Lardeau, D., Lacape, G. (1994). Serum fatty acid profiles in type I and ii diabetes;metablic alteration of fatty acids of the main serumlipids. Diab Res Clin Pract, 23:169-177.
9. Warrier, P.K., Nambiar, V.P.K., Ramankutty, C. (1995). Indian Medicinal Plants. Orient Longman Limited, Madras, pp. 381–383.
10. Maurya, R., Ray, A.B., Duah, F.K., Slatkin, D.J., Schiff, P.L. (1984). Constituents of Pterocarpus marsupium. J Nat Prod,47:179-181.
11. Manickam, M., Ramanathan, M., Jahromi, M.A., Chansouria, J.P., Ray, A.B. (1997). Antihyperglycemic activity of phenolics from Pterocarpus marsupium. J Nat Prod, 60: 609-610.
12. Indian Council of Medical Research (ICMR). (1998). Flexible open trial of vijayasar in case of newly diagnosed non-insulin dependent diabetes mellitus. Ind J Med Res, 108:24-29.
13. Murugan, P., Pari, L., Chippada Appa Rao. (2008). Effect of tetrahydrocurcumin on insulin receptors status in type 2 diabetic rats: Studies on insulin binding to erythrocytes. J Biosci, 33(1): 63-72.
14. Murugan, P., Pari L. (2006). Effect of tetrahydrocurcumin on lipid peroxidation and lipids in streptozotocin - nicotinamide induced diabetic rats. Basic Clin Pharmacol Toxicol, 99:122-127.
15. Murugan, P., Pari L. (2007). Influence of tetrahydrocurcumin on erythrocyte membrane bound enzymes and antioxidant status in experimental type 2 diabetic rats. J Ethanopharmacol, 113: 479–486.
16. Murugan, P., Pari L. (2006). Antioxidant effect of tetrahydrocurcumin in streptozotocin - nicotinamide induced diabetic rats. Life sci, 79: 1720-1728.
17. Pari, L., Murugan P. (2004). Protective role of tetrahydrocurcumin against erythromycin estolate induced hepatotoxicity. Pharmacol Res, 49 (5): 481-486.
18. Murugan, P., Pari L. (2007). Influence of tetrahydrocurcumin on erythrocyte membrane bound enzymes and antioxidant status in experimental type 2 diabetic rats. J Ethanopharmacol, 113: 479–486.
19. Murugan, P., Pari L, Chippada Appa Rao. (2008). Effect of tetrahydrocurcumin on insulin receptors status in type 2 diabetic rats: Studies on insulin binding to erythrocytes. J Biosc, 33(1): 63-72.
20. Pari, L., Murugan P. (2005). Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. J Basic Clin Physiol Pharmacol, 16: 257-274.
21. Pari, L., Murugan P. (2007). Changes in glycoprotein components in streptozotocin - nicotinamide induced type 2 diabetes: Influence of tetrahydrocurcumin from Curcuma longa. Plant Foods Hum Nutr, 62(1): 25-29.
22. Pari, L., Murugan P. (2007). Antihyperlipidaemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic rats. Renal Failure, 29: 881-889.
23. Masiello, P., Broca, C., Gross, R., Roye, M., Manteghetti, M., Hillaire-Buys, D., Novelli, M., Ribes, G. (1998). Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes, 47: 224-229.
24. Klimes, I., Sebokova, E., Gasperikova, D., Mitkova, A., Kuklova, S., Bohov, P. (1998). Search for extra pancreatic effects of new oral hypoglycemic agent A-1466. 1: Oral glucose tolerance tests in normal and hereditary insulin resistant rats. Endocrinol Reg, 32: 115-123.
25. Pari L, Amarnath Satheesh M. (2006). Effect of pterostilbene on hepatic key enzymes of glucose metabolism in streptozotocin- and nicotinamide-induced diabetic rats. Life Sci, 79, 641–645.
26. Pari, L., Murugan, P. (2007). Tetrahydrocurcumin prevents brain lipid peroxidation in streptozotocin-induced diabetic rats. J Med Food, 10 (2): 323-329.
27. Lott, J.A., Turner, K. (1932). Evaluation of trinder’s glucose oxidase method for measuring glucose in serum and urine. Clin Chem, 21/12: 1754-1760.
28. Drabkin, D.L, Austin, J.M. (1932). Spectrophotometric constants for common haemoglobin derivatives in human, dog and rabbit blood. J Biol Chem, 98: 719-733.
29. Sudhakar Nayak, S., Pattabiraman, T. (1982). A new colorimetric method for the estimation of glycosylated haemoglobin. Clin Chim Acta 1981; 109: 267-274.
30. Bannon, P. (1982). Effect of pH on the elimination of the labile fraction of glycosylated haemoglobin. Clin Chem, 28: 2183.
31. Morrison, W.R., Smith, L.M. (1964). Preparations of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride methanol. J Lipid Res, 5: 600-607.
32. Duncan, B.D. (1957). Multiple range tests for correlated and heteroscedastic means. Biometrics, 13: 359-364.
33. Cowie, C.C., Eberhardt, M.S. (1996). Diabetes: Vital statistics. American Diabetes Association, Alexandria, VA: 1-4.
34. DeFronzo, R.A., Bonadonna, R.C., Ferrannini, E. (1992). Pathogenesis of NIDDM: a balanced overview. Diabetes Care, 15: 318-368.
35. Olefsky, J.M., Nolan, J. (1995). Insulin resistance and NIDDM: Cellular and molecular mechanisms. Am J Clin Nutr, 61: 980S-986S.
36. Haffner, S.M. (1991). Compositional changes in lipoproteins of subjects with non-insulin-dependent diabetes mellitus. J Lab Clin Med, 118: 109-110.
37. Gandhi, H.R. (2001). Diabetes and coronary artery disease: Importance of risk factors. Cardiol Today, 1: 31-34.
38. American Diabetes Association. (1989). Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Consensus statement. Diabetes Care, 12: 573-579.
39. Zavaroni, I., Bonora, E., Pagliara, M., Dall'Aglio, E., Luchetti, L., Buonanno, G., Bonati, P.A., Bergonzani, M., Gnudi, L., Passeri, M. (1989). Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. New Engl J Med, 320: 702-706.
40. Tilvis, R.S., Miettinen, T.A. (1985). Fatty acid compositions of serum lipids, erythrocytes, and platelets in insulin-dependent diabetic women. J Clin Endocrinol Metab, 61:741-745.
41. Demaison, L., Sergiel, J.P., Moreau, D., Grynberg, A. (1994). Influence of the phospholipid n-6/n-3 polyunsaturated fatty acid ratio on the mitochondrial oxidative metabolism before and after myocardial ischemia. Biochim Biophys Acta, 1227:53-59.
42. Brenner, R.R. (1977). Regulatory function of delta6 desaturate key enzyme of polyunsaturated fatty acid synthesis. Adv Exp Med Biol, 83:85-101.
43. Eck, M.G., Wynn, J.O., Carter, W.J., Faas, F.H. (1979). Fatty acid desaturation in experimental diabetes mellitus. Diabetes, 28:479-485.
2. Haffner, S.M., Lehto, S., Rönnemaa, T., Pyörälä, K., Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med, 339: 229-234.
3. Eder, H.A., Bergman, M. (1990). Metabolism of plasma lipids and lipoproteins.
Diabetes Mellitus: Theory and Practice, 3rd ed. Medical Examination Publishing, New York. 61-72.
4. UKPDS. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352: 837-853.
5. Deedwania, P.C. (2000) Hypertension and diabetes: new therapeutic options. Arch Intern Med, 160:1585-1594.
6. Cameron, N.E., Cotter, M.A. (1999). Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pract, 45:137-146.
7. Faas, F.H., Dang, A.Q., Kemp, K., Norman, J., Carter, W.J. (1988). Red blood cell and plasma fatty acid composition in diabetes mellitus. Metabolism 37:711-713.
8. Seigneur, M., Freyburger, G., Gin, H., Claverie, M., Lardeau, D., Lacape, G. (1994). Serum fatty acid profiles in type I and ii diabetes;metablic alteration of fatty acids of the main serumlipids. Diab Res Clin Pract, 23:169-177.
9. Warrier, P.K., Nambiar, V.P.K., Ramankutty, C. (1995). Indian Medicinal Plants. Orient Longman Limited, Madras, pp. 381–383.
10. Maurya, R., Ray, A.B., Duah, F.K., Slatkin, D.J., Schiff, P.L. (1984). Constituents of Pterocarpus marsupium. J Nat Prod,47:179-181.
11. Manickam, M., Ramanathan, M., Jahromi, M.A., Chansouria, J.P., Ray, A.B. (1997). Antihyperglycemic activity of phenolics from Pterocarpus marsupium. J Nat Prod, 60: 609-610.
12. Indian Council of Medical Research (ICMR). (1998). Flexible open trial of vijayasar in case of newly diagnosed non-insulin dependent diabetes mellitus. Ind J Med Res, 108:24-29.
13. Murugan, P., Pari, L., Chippada Appa Rao. (2008). Effect of tetrahydrocurcumin on insulin receptors status in type 2 diabetic rats: Studies on insulin binding to erythrocytes. J Biosci, 33(1): 63-72.
14. Murugan, P., Pari L. (2006). Effect of tetrahydrocurcumin on lipid peroxidation and lipids in streptozotocin - nicotinamide induced diabetic rats. Basic Clin Pharmacol Toxicol, 99:122-127.
15. Murugan, P., Pari L. (2007). Influence of tetrahydrocurcumin on erythrocyte membrane bound enzymes and antioxidant status in experimental type 2 diabetic rats. J Ethanopharmacol, 113: 479–486.
16. Murugan, P., Pari L. (2006). Antioxidant effect of tetrahydrocurcumin in streptozotocin - nicotinamide induced diabetic rats. Life sci, 79: 1720-1728.
17. Pari, L., Murugan P. (2004). Protective role of tetrahydrocurcumin against erythromycin estolate induced hepatotoxicity. Pharmacol Res, 49 (5): 481-486.
18. Murugan, P., Pari L. (2007). Influence of tetrahydrocurcumin on erythrocyte membrane bound enzymes and antioxidant status in experimental type 2 diabetic rats. J Ethanopharmacol, 113: 479–486.
19. Murugan, P., Pari L, Chippada Appa Rao. (2008). Effect of tetrahydrocurcumin on insulin receptors status in type 2 diabetic rats: Studies on insulin binding to erythrocytes. J Biosc, 33(1): 63-72.
20. Pari, L., Murugan P. (2005). Effect of tetrahydrocurcumin on blood glucose, plasma insulin and hepatic key enzymes in streptozotocin induced diabetic rats. J Basic Clin Physiol Pharmacol, 16: 257-274.
21. Pari, L., Murugan P. (2007). Changes in glycoprotein components in streptozotocin - nicotinamide induced type 2 diabetes: Influence of tetrahydrocurcumin from Curcuma longa. Plant Foods Hum Nutr, 62(1): 25-29.
22. Pari, L., Murugan P. (2007). Antihyperlipidaemic effect of curcumin and tetrahydrocurcumin in experimental type 2 diabetic rats. Renal Failure, 29: 881-889.
23. Masiello, P., Broca, C., Gross, R., Roye, M., Manteghetti, M., Hillaire-Buys, D., Novelli, M., Ribes, G. (1998). Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes, 47: 224-229.
24. Klimes, I., Sebokova, E., Gasperikova, D., Mitkova, A., Kuklova, S., Bohov, P. (1998). Search for extra pancreatic effects of new oral hypoglycemic agent A-1466. 1: Oral glucose tolerance tests in normal and hereditary insulin resistant rats. Endocrinol Reg, 32: 115-123.
25. Pari L, Amarnath Satheesh M. (2006). Effect of pterostilbene on hepatic key enzymes of glucose metabolism in streptozotocin- and nicotinamide-induced diabetic rats. Life Sci, 79, 641–645.
26. Pari, L., Murugan, P. (2007). Tetrahydrocurcumin prevents brain lipid peroxidation in streptozotocin-induced diabetic rats. J Med Food, 10 (2): 323-329.
27. Lott, J.A., Turner, K. (1932). Evaluation of trinder’s glucose oxidase method for measuring glucose in serum and urine. Clin Chem, 21/12: 1754-1760.
28. Drabkin, D.L, Austin, J.M. (1932). Spectrophotometric constants for common haemoglobin derivatives in human, dog and rabbit blood. J Biol Chem, 98: 719-733.
29. Sudhakar Nayak, S., Pattabiraman, T. (1982). A new colorimetric method for the estimation of glycosylated haemoglobin. Clin Chim Acta 1981; 109: 267-274.
30. Bannon, P. (1982). Effect of pH on the elimination of the labile fraction of glycosylated haemoglobin. Clin Chem, 28: 2183.
31. Morrison, W.R., Smith, L.M. (1964). Preparations of fatty acid methyl esters and dimethylacetals from lipids with boron fluoride methanol. J Lipid Res, 5: 600-607.
32. Duncan, B.D. (1957). Multiple range tests for correlated and heteroscedastic means. Biometrics, 13: 359-364.
33. Cowie, C.C., Eberhardt, M.S. (1996). Diabetes: Vital statistics. American Diabetes Association, Alexandria, VA: 1-4.
34. DeFronzo, R.A., Bonadonna, R.C., Ferrannini, E. (1992). Pathogenesis of NIDDM: a balanced overview. Diabetes Care, 15: 318-368.
35. Olefsky, J.M., Nolan, J. (1995). Insulin resistance and NIDDM: Cellular and molecular mechanisms. Am J Clin Nutr, 61: 980S-986S.
36. Haffner, S.M. (1991). Compositional changes in lipoproteins of subjects with non-insulin-dependent diabetes mellitus. J Lab Clin Med, 118: 109-110.
37. Gandhi, H.R. (2001). Diabetes and coronary artery disease: Importance of risk factors. Cardiol Today, 1: 31-34.
38. American Diabetes Association. (1989). Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Consensus statement. Diabetes Care, 12: 573-579.
39. Zavaroni, I., Bonora, E., Pagliara, M., Dall'Aglio, E., Luchetti, L., Buonanno, G., Bonati, P.A., Bergonzani, M., Gnudi, L., Passeri, M. (1989). Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. New Engl J Med, 320: 702-706.
40. Tilvis, R.S., Miettinen, T.A. (1985). Fatty acid compositions of serum lipids, erythrocytes, and platelets in insulin-dependent diabetic women. J Clin Endocrinol Metab, 61:741-745.
41. Demaison, L., Sergiel, J.P., Moreau, D., Grynberg, A. (1994). Influence of the phospholipid n-6/n-3 polyunsaturated fatty acid ratio on the mitochondrial oxidative metabolism before and after myocardial ischemia. Biochim Biophys Acta, 1227:53-59.
42. Brenner, R.R. (1977). Regulatory function of delta6 desaturate key enzyme of polyunsaturated fatty acid synthesis. Adv Exp Med Biol, 83:85-101.
43. Eck, M.G., Wynn, J.O., Carter, W.J., Faas, F.H. (1979). Fatty acid desaturation in experimental diabetes mellitus. Diabetes, 28:479-485.
Article Sidebar
Published
Jul 20, 2023
Article Details
How to Cite
Pidaran Murugan. (2023). MODULATORY EFFECT OF PTEROSTILBENE ON CHANGES IN THE FATTY ACID COMPOSITION IN STREPTOZOTOCIN - NICOTINAMIDE INDUCED DIABETES. Journal of Population Therapeutics and Clinical Pharmacology, 30(4), 626-637. https://doi.org/10.53555/jptcp.v30i4.2398
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biography
Pidaran Murugan
Assistant professor of Biochemistry, Centre for Distance and Online Education, Bharathidhasan University, 620024. Tamil Nadu, India. India. Tel: + 9791620088
How to Cite
Pidaran Murugan. (2023). MODULATORY EFFECT OF PTEROSTILBENE ON CHANGES IN THE FATTY ACID COMPOSITION IN STREPTOZOTOCIN - NICOTINAMIDE INDUCED DIABETES. Journal of Population Therapeutics and Clinical Pharmacology, 30(4), 626-637. https://doi.org/10.53555/jptcp.v30i4.2398